Anavex Life Sciences Corp. Statistics
Share Statistics
Anavex Life Sciences Corp. has 84.80M shares outstanding. The number of shares has increased by 3.3% in one year.
| Shares Outstanding | 84.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 82.10M |
| Failed to Deliver (FTD) Shares | 103 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 18.31M, so 21.59% of the outstanding shares have been sold short.
| Short Interest | 18.31M |
| Short % of Shares Out | 21.59% |
| Short % of Float | 22.3% |
| Short Ratio (days to cover) | 24.67 |
Valuation Ratios
The PE ratio is -11 and the forward PE ratio is -14.32.
| PE Ratio | -11 |
| Forward PE | -14.32 |
| PS Ratio | 0 |
| Forward PS | 49.6 |
| PB Ratio | 3.68 |
| P/FCF Ratio | -18.81 |
| PEG Ratio | n/a |
Enterprise Valuation
Anavex Life Sciences Corp. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 12.32, with a Debt / Equity ratio of 0.
| Current Ratio | 12.32 |
| Quick Ratio | 12.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -57.84 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on capital (ROIC) is -39.31%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -39.31% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.19M |
| Employee Count | 40 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 7.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -4.86% in the last 52 weeks. The beta is 0.6, so Anavex Life Sciences Corp.'s price volatility has been higher than the market average.
| Beta | 0.6 |
| 52-Week Price Change | -4.86% |
| 50-Day Moving Average | 7.2 |
| 200-Day Moving Average | 5.51 |
| Relative Strength Index (RSI) | 51.68 |
| Average Volume (20 Days) | 1.15M |
Income Statement
In the last 12 months, Anavex Life Sciences Corp. had revenue of $0 and earned -$47.51M in profits. Earnings per share was $-0.6.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -55.76M |
| Net Income | -47.51M |
| EBITDA | -55.76M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has $151.02M in cash and $0 in debt, giving a net cash position of $151.02M.
| Cash & Cash Equivalents | 151.02M |
| Total Debt | 0 |
| Net Cash | 151.02M |
| Retained Earnings | -293.07M |
| Total Assets | 141.53M |
| Working Capital | 129.78M |
Cash Flow
In the last 12 months, operating cash flow was -$27.79M and capital expenditures $0, giving a free cash flow of -$27.79M.
| Operating Cash Flow | -27.79M |
| Capital Expenditures | 0 |
| Free Cash Flow | -27.79M |
| FCF Per Share | -0.35 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
AVXL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.13% |
| FCF Yield | -3.9% |
Analyst Forecast
The average price target for AVXL is $46, which is 447% higher than the current price. The consensus rating is "Buy".
| Price Target | $46 |
| Price Target Difference | 447% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Oct 7, 2015. It was a backward split with a ratio of 1:4.
| Last Split Date | Oct 7, 2015 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 32.04 |
| Piotroski F-Score | 1 |